Avalo Therapeutics (AVTX) Notes Payables (2022 - 2025)

Avalo Therapeutics' (AVTX) quarterly Notes Payables came in at $370000.0 in Q2 2025, up 2.78% on a QoQ basis from $360000.0 in Q1 2025.

Analysis

Avalo Therapeutics (AVTX) Notes Payables (2022 - 2025) Analysis & Trends

Avalo Therapeutics (AVTX) has 4 years of Notes Payables data on file, last reported at $370000.0 in Q2 2025.

Quarterly Notes Payables changed N/A year-over-year to $370000.0 in Q2 2025, while the trailing twelve-month figure through Jun 2025 was $370000.0 (changed N/A YoY) and the FY2024 annual result came in at $360000.0, changed N/A from the prior year.
Notes Payables advanced to $370000.0 in Q2 2025, from $360000.0 in the prior quarter.
In the past five years, Notes Payables ranged from a high of $14.1 million in Q2 2023 to a low of $360000.0 in Q4 2024.
A 4-year average of $4.7 million and a median of $2.6 million in 2022 frame the typical range for Notes Payables.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	138.47 Bn	130.62 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.18 Bn	77.19 Bn	3.93 Bn
3	Argenx Se	63.38 Bn	58.19 Bn	1.37 Bn
4	Moderna	58.09 Bn	52.95 Bn	52.00 Mn
5	Revolution Medicines	44.33 Bn	44.33 Bn	-
6	BeOne Medicines	40.02 Bn	34.92 Bn	1.53 Bn
7	Alnylam Pharmaceuticals	35.57 Bn	32.27 Bn	992.69 Mn
8	Royalty Pharma	28.45 Bn	27.61 Bn	-
9	Insmed	27.48 Bn	26.32 Bn	358.27 Mn
10	Avalo Therapeutics	843.26 Mn	843.26 Mn	-

Historic Data

Download Data